Italian Medicines Agency withdraws GMP certificate from Indian manufacturer

By Zachary Brennan

- Last updated on GMT

Related tags Manufacturing Quality control

Little-known Sri Krisha was hit with the warning letter
Little-known Sri Krisha was hit with the warning letter
The agency issued a warning letter and withdrew the GMP (Good Manufacturing Practice) certificate from Hyderabad, India-based Sri Krishna Pharmaceuticals for 10 GMP deviations found during an inspection at its Nacharam granulation plant in December.

In particular, the Italian agency said its main concerns were that drugs that failed to meet established quality control criteria are not rejected.

Employees at Sri Krishna “routinely use the PC administrator privileges to set the controlling time and date settings back to over-write previously collected failing and/or undesirable sample results. This practice is performed until passing and/or desirable results are achieved​.”

In addition, inspectors found that company employees routinely performed “trial” injections of sample aliquots prior to performing the official analysis. The results of these trials are not reported, and were found to “differ significantly from the subsequent reported results… The resulting raw data chromatogram files were often found to have been deleted and unavailable for review​.”

The company’s electronic records also were seen as not meeting systems validation ensuring they are trustworthy, reliable and generally equivalent to paper records

Inspectors also found “torn and discarded controlled manufacturing batch records for a variety of different products issued by the Quality Unit​.”

Meanwhile, five batch records were compared with the archived manufacturing one and it was ascertained that no records had been made for duplicate issuance of these five batches chosen for review.

Finally, the Italian regulators said that the current GMP certificates issued in March 2013 and November 2013 are invalid. “It is proposed to withdraw also the GMP Certificate issued by Baden – Württemberg (Germany) on 04 August 2014​,” the Italian agency said.

However, the agency did not move to ban products from the company as “there is no reason of concern regarding the quality of the batches of finished products for the following reasons: - only intermediates granules to be further processed by other manufacturing plants of finished products are manufactured in the inspected units; - the finished product is further tested by the batch release site before the release on the market. If no full testing (including impurities) of the finished product has been performed before the release, National Competent Authorities should consider immediate recall of the already released batches and prohibition of supply of further batches using Sri Krishna sourced granules​.

As an alternative National Competent Authorities may request Marketing Authorisation Holders to conduct a risk assessment in order to evaluate the risk to product quality and patients from the issues identified.

The GMP certificate withdrawal does not impact any of Sri Krishna's API manufacturing sites.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more